Editorial
Boceprevir and Calcineurin Inhibitors â is there a Role for Treating Hepatitis C Recurrence after Liver Transplantation?
Sandeep Mukherjee*
Section of Gastroenterology and Hepatology, Nebraska Medical Center, USA
- *Corresponding Author:
- Sandeep Mukherjee
Section of Gastroenterology and Hepatology
Nebraska Medical Center
Omaha, NE 68198-3285, USA
Tel: 402-559-3139
Fax: 402-559-6132
E-mail: [email protected]
Received Date: September 04, 2012; Accepted Date: September 05, 2012; Published Date: September 11, 2012
Citation: Mukherjee S (2012) Boceprevir and Calcineurin Inhibitors – is there a Role for Treating Hepatitis C Recurrence after Liver Transplantation? J Antivir Antiretrovir 4: xv-xvi. doi: 10.4172/jaa.1000e106
Copyright: © 2012 Mukherjee S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Cirrhosis from Hepatitis C (HCV) remains the leading indication for liver transplantation in the United States with recurrent disease leading to cirrhosis in 42% of patients by 5 years post-transplant. Aspegylated interferon (PIF) and ribavirin (RBV) are only effective in approximately 30% of patients with recurrent HCV genotype 1, this has led to recurrent HCV emerging as an important but controversial indication for retransplantation. On the other hand, the approval of protease inhibitors (PI’s) for the treatment of pre-transplant patients with HCV genotype 1 in 2011 has rapidly transformed our management of this ubiquitous disease.
